SCRI

"Our reach and impact is made possible by the passion and dedication of our colleagues, physicians and staff." David Spigel, MD Chief Scientific Officer, Sarah Cannon Research Institute Collaboration. Innovation. Inspiration. Those three words summarize the last year at Sarah Cannon Research Institute (SCRI). Advancing cancer therapies cannot be done alone. The collective resolve to develop next-generation therapies is dependent on the contributions and collaborations of partners across the oncology community. Our partnerships with sponsors and physicians across the network are enabling us to deliver more impact to even more communities and more people with cancer. While partnership is essential, innovation is the heartbeat of our mission. SCRI experts presented key clinical data at numerous scientific conferences and medical meetings worldwide and published more than 300 manuscripts in peer-reviewed journals. We ended the year with record-setting research numbers, thanks to the collaboration and innovation of our strong network of more than 1,300 physicians. SCRI's research network of community- based trial sites reaches 1 in 5 patients with cancer in the United States. Our reach and impact is made possible by the passion and dedication of our colleagues, physicians and staff. As we look back on the last year, I'm immensely proud and inspired by all the success at SCRI. The strides we are making today with our community-based clinical trials are paving the way for the therapies of tomorrow, bringing hope to patients everywhere.

• Cover